Marker Therapeutics
MRKR
70 hedge funds and large institutions have $134M invested in Marker Therapeutics in 2019 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 15 increasing their positions, 12 reducing their positions, and 14 closing their positions.
100% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 14
79% more call options, than puts
Call options by funds: $1.02M | Put options by funds: $567K
32% more capital invested
Capital invested by funds: $101M → $134M (+$32.6M)
25% more funds holding
Funds holding: 56 → 70 (+14)
25% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 12
3.43% more ownership
Funds ownership: 33.65% → 37.08% (+3.4%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$9.68M |
| 2 |
State Street
Boston,
Massachusetts
|
+$2.83M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.18M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$821K |
| 5 |
OCM
Osterweis Capital Management
San Francisco,
California
|
+$709K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
-$5.35M |
| 2 |
LCM
Laurion Capital Management
New York
|
-$1.4M |
| 3 |
Millennium Management
New York
|
-$1.17M |
| 4 |
Barclays
London,
United Kingdom
|
-$610K |
| 5 |
Goldman Sachs
New York
|
-$474K |
MRKR Hedge Fund Activity: Q2 2019 in Review
70 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Marker Therapeutics (MRKR) for Q2 2019, worth a combined $134M — up 32% from $101M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new MRKR positions and 14 closed out — a net gain of 14 holders — while 15 added to existing stakes and 12 trimmed.
The largest buyer was BlackRock, adding an estimated $9.68M. The largest seller was 683 Capital Management, cutting an estimated $5.35M.
- 70 institutional investors held Marker Therapeutics (MRKR) as of Q2 2019, up from 56 in Q1 2019.
- Funds reported $134M of Marker Therapeutics stock for Q2 2019, up 32% quarter-over-quarter.
- 28 funds opened new Marker Therapeutics positions in Q2 2019 and 14 closed out, a net change of +14 holders.
- The largest Marker Therapeutics buyer in Q2 2019 was BlackRock, an estimated $9.68M added.
- The largest Marker Therapeutics seller in Q2 2019 was 683 Capital Management, an estimated $5.35M sold.
Based on aggregated 13F filings for Q2 2019.